Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the ...
NCX 470 New Drug Application (NDA) filing in the United States: expected in H1 2026. NCX 470 New Drug Application (NDA) filing in China: expected after submission in the U.S. Results from NCX 470 ...
Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that once daily dosing of NCX 470 0.1%, a novel nitric oxide (NO)-donating bimatoprost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results